Retrospective Study of the Use of Everolimus/Exemestane in the Treatment of Oestrogen Receptor Positive (ER plus ) Metastatic Breast Cancer (MBC): The Kent Oncology Network Experience

被引：0
|
作者：
Ang, J. E. [1 ]
Jyothirmayi, R. [1 ]
Mithal, N. [1 ]
Abson, C. [1 ]
Burcombe, R. [1 ]
Harper-Wynne, C. [1 ]
机构：
[1] Kent Oncol Ctr, Maidstone, Kent, England
来源：
CLINICAL ONCOLOGY | 2015年 / 27卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E9 / E9
页数：1
相关论文
共 50 条
  • [1] Everolimus plus exemestane for hormone resistant metastatic breast cancer (MBC): A single institutional experience.
    Foltran, Luisa
    Bertola, Manuela
    Del Conte, Alessandro
    Lo Re, Giovanni
    Bestetti, Alessandro
    Sandri, Paolo
    Saracchini, Silvana
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [2] Cost-effectiveness analysis of everolimus plus exemestane versus exemestane alone for treatment of hormone receptor positive metastatic breast cancer
    Vakaramoko Diaby
    Georges Adunlin
    Simon B. Zeichner
    Kiran Avancha
    Gilberto Lopes
    Stefan Gluck
    Alberto J. Montero
    Breast Cancer Research and Treatment, 2014, 147 : 433 - 441
  • [3] Erratum to: Cost-effectiveness analysis of everolimus plus exemestane versus exemestane alone for treatment of hormone receptor positive metastatic breast cancer
    Vakaramoko Diaby
    Georges Adunlin
    Simon B. Zeichner
    Kiran Avancha
    Gilberto Lopes
    Stefan Gluck
    Alberto J. Montero
    Breast Cancer Research and Treatment, 2014, 147 : 443 - 443
  • [4] Cost-effectiveness of everolimus plus exemestane in postmenopausal hormone receptor positive metastatic breast cancer
    Zeichner, Simon B.
    Avancha, Kiran Kumar Venkata Raja
    Lopes, Gilberto
    Gluck, Stefan
    Montero, Alberto J.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [5] BRAWO - breast cancer treatment with Afinitor® (Everolimus) and exemestane for ER plus women
    Schuetz, F.
    Jackisch, C.
    Tesch, H.
    Bloch, W.
    Muth, M.
    Kreuzeder, J.
    Lueftner, D.
    ONKOLOGIE, 2013, 36 : 158 - 159
  • [6] Real-world experience of exemestane-everolimus (EXE-EVE) in elderly patients with hormone-receptor positive (HR plus ) metastatic breast cancer (MBC).
    Redana, Stefania
    Papadimitraki, Elisavet
    Okonji, David Odhiambo
    Khabra, Komel
    Thanopoulou, Eirini
    Chiramel, Jaseela
    Papanastasopoulos, Panagiotis
    Wardley, Andrew M.
    Hogg, Martin S.
    Howell, Sacha Jon
    Zucchini, Giorgia
    Kenny, Laura M.
    Ring, Alistair E.
    Johnston, Stephen R. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [7] A Network Meta-Analysis of Everolimus plus Exemestane versus Chemotherapy in the First and Second Line Treatment of Estrogen Receptor Positive Metastatic Breast Cancer
    Generali, D.
    Venturini, S.
    Rognoni, C.
    Ciani, O.
    Pusztai, L.
    Loi, S.
    Jerusalem, G.
    Bottini, A.
    Tarricone, R.
    ANNALS OF ONCOLOGY, 2015, 26 : 9 - 9
  • [8] Statin use in patients with hormone receptor-positive metastatic breast cancer treated with everolimus and exemestane
    Lee, Kyoungmin
    Noh, Eunjin
    Moon, Seok Joo
    Joo, Yoonjung Yoonie
    Kang, Eun Joo
    Seo, Jae Hong
    Park, In Hae
    CANCER MEDICINE, 2023, 12 (05): : 5461 - 5470
  • [9] SAFETY OF COMBINED EXEMESTANE AND EVEROLIMUS IN POSTMENOPAUSAL HORMONE RECEPTOR POSITIVE METASTATIC BREAST CANCER PATIENTS - A RETROSPECTIVE ANALYSIS
    Gilchrist, Jenny
    Todd, J.
    Kefford, R.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2014, 10 : 176 - 176
  • [10] Evaluation of safety and activity of everolimus plus exemestane in metastatic breast cancer: a single institution experience
    Ferrarini, I.
    Bertolini, I.
    Fancelli, S.
    De Angelis, C.
    Fontana, A.
    Salvadori, B.
    Landucci, E.
    Michelotti, A.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2015, 26 : 15 - 16
12345